Anzeige
Mehr »
Login
Mittwoch, 26.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
Die DeepSeek-Revolution: Pioneer AIs Multi-Agent-Strategie lässt die Konkurrenz alt aussehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJEC | ISIN: CA45257F2008 | Ticker-Symbol: TQB
Tradegate
26.02.25
16:18 Uhr
0,384 Euro
+0,034
+9,71 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNOPRECISE ANTIBODIES LTD Chart 1 Jahr
5-Tage-Chart
IMMUNOPRECISE ANTIBODIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,4140,43022:33
0,3320,33622:01

Aktuelle News zur IMMUNOPRECISE ANTIBODIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:42ImmunoPrecise & RIBOPRO Partner for AI-Powered Antibody Discovery2
14:12ImmunoPrecise Antibodies Ltd.: IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy167ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering...
► Artikel lesen
MoImmunoPrecise Antibodies appoints Joseph Scheffler interim CFO4
IMMUNOPRECISE ANTIBODIES Aktie jetzt für 0€ handeln
MoImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer2
03.02.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer2
28.01.ImmunoPrecise Antibodies Ltd. (IPA) Unveils AI-Developed GLP-1 Therapies for Type 2 Diabetes and Obesity, Pioneering New Frontiers in Biotech Innovation3
27.01.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer2
22.01.What's Going On With ImmunoPrecise Antibodies Stock Wednesday?5
20.01.ImmunoPrecise Antibodies Ltd. (IPA) Launches AI-Powered Drug Discovery Pipeline, Revolutionizing Therapeutic Development with LENSai Platform8
17.01.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer-
17.01.ImmunoPrecise launches AI-driven drug discovery pipeline5
03.01.ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer2
02.01.ImmunoPrecise Antibodies finance chief to step down3
01.01.ImmunoPrecise Antibodies CFO Kristin Taylor To Resign1
23.12.24ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer4
19.12.24ImmunoPrecise Antibodies Ltd.: IPA to Present at The Microcap Conference 2025421VICTORIA, BC / ACCESSWIRE / December 19, 2024 / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced...
► Artikel lesen
10.12.24ImmunoPrecise Antibodies: Q2 Earnings Insights9
10.12.24ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025187VICTORIA, British Columbia--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial...
► Artikel lesen
10.12.24ImmunoPrecise Antibodies Ltd. - 6-K, Report of foreign issuer3
09.12.24A Preview Of ImmunoPrecise Antibodies' Earnings3
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2